Press Сentre
Наши новости
Artificial Intelligence (AI) is now actively used in various industries, transforming and improving the processes efficiency. Medicine and pharmaceuticals are no exception, they are industries where AI technologies are being introduced into routine practice.
Development of new drugs is a long and expensive process; it is assumed that AI, by ...
27.04.2024
ChemRar Group and Pharmaceutical Health Corporation S.A.S, national pharmaceutical distributor in Colombia, announce the signing of the agreement for the supply of five anticancer products: TEMOZOLOMIDE (INN Temozolomide), LANGOTER (INN Gefitinib), SUNITINIB-CHEMRAR (INN Sunitinib), POTARBIN (INN Pazopanib) and LAPATINIB-CHEMRAR (INN Lapatinib). ...
15.04.2024
Andrey Aleksandrovich Ivashchenko, the Chairman of the Board of Directors of ChemRar Group, spoke at “Road to Sovereignty in Pharma and Healthcare” discussion organized by Kommersant Publishing House.
In June 2023, the Russian Government approved the Pharma-2030 Pharmaceutical Industry Development Strategy prepared by the Russian Ministry of ...
08.04.2024
April 2, a cycle of export-themed meetings has commenced at the office of the Russian Venture Company arranged by the National Champions Association in 2024.
The Export Champions Program is to support the international business activities of the rapid-growing hi-tech companies. The first topic on the agenda was the export of the pharmaceuticals ...
05.04.2024
Elpida informs that the auctions for centralized procurement of innovative medicines for HIV treatment have been successfully completed. In particular, the auctions for supply of 5,116,140 capsules (or 170,538 packs) of ELPIDA® COMBI and 13,382,820 capsules (or 446,094 packs) of ELPIDA® were held on January 17 and February 19, respectively.
...
07.03.2024
Over the past year, patient organizations have repeatedly reported that Russian HIV patients do not have enough dolutegravir . The original drug under the Tivicay brand is supplied to Russia by the British GSK. Initially, the active substance was protected by a patent until 2026, but then its validity was extended until 2029.
As Kommersant ...
30.01.2024
ChemRar Group provides Russian scientists with access to one of the world's largest collections of chemical substances for in vitro screening. The collection contains more than 1.6 million compounds and more than 100 ready-made focused libraries for medicinal chemistry projects.
The development of domestic innovative drugs is one of the ...
15.12.2023
This year, a large number of Chinese guests - suppliers of pharmaceutical ingredients , equipment and materials - became noticeable. On the first day, two main blocks of topics were covered: ensuring the development of the innovative potential of the Russian pharmaceutical industry, lessons from the Pharma-2020 program and their importance for the ...
08.12.2023
Actualmente, ChemRar y la empresa mexicana «Distribuidora y Exportadora de Medicamentos, S.A. de C.V. (DIEMSA)» han acordado sobre el registro sanitario en México y los suministros posteriores al país de medicamentos rusos para la terapia de enfermedades oncológicas.
En particular, se trata del fármaco antitumoral SUNITINIB (pertenece a ...
08.12.2023
To ensure technological sovereignty, leading universities could become new “development institutions” that, based on technological entrepreneurship, will bridge the gap between science and industry in key areas.
Andrey Ivashchenko, Chairman of the Board of Directors of the ChemRar Group, Head of the Department of Innovative Pharmaceuticals, ...
01.12.2023
Over the past decade, domestic pharmaceuticals have made a huge leap. But even more ambitious goals are set for it in the Pharma-2030 Development Strategy. How the leading companies in the industry plan to achieve them was told to “RG” by the Chairman of the Board of Directors of the ChemRar Group, Doctor of Technical Sciences, Professor of the ...
16.11.2023
At the First Moscow State Medical University named after I.M. Sechenov began clinical trials of a drug for the treatment of depression and panic disorder. The medicine was developed by the ChemRar group of companies, a leading domestic developer and manufacturer of innovative drugs. To create a high-tech production of active pharmaceutical ...
26.10.2023
Публикации в печатных и электронных СМИ
Видео
Фото
